Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target

Benzinga · 1d ago
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.